Ireland’s Chanelle is aiming at US liquids

Chanelle Pharma, “Ireland’s largest manufacturer of generic pharmaceuticals”, is spending €11 million (US$13 million) on a dedicated facility to produce liquid formulations for the US market. The plant, which is designed to comply with both US Food and Drug Administration (FDA) and European quality standards, forms part of an overall €86 million investment program that the firm has just unveiled.